Psychiatric disorders associated with Cushing's syndrome: Epidemiology, pathophysiology and treatment

CNS Drugs

Volumn 15, Issue 5, 2001, Pages 361-373

  Sonino, Nicoletta ^a   Fava, Giovanni A ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; AMINOGLUTETHIMIDE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BROMOCRIPTINE; CLONAZEPAM; CYPROHEPTADINE; DOPAMINE RECEPTOR STIMULATING AGENT; GLUCOCORTICOID; HORMONE INHIBITOR; HYDROCORTISONE; KETANSERIN; KETOCONAZOLE; LISURIDE; METERGOLINE; METYRAPONE; MIFEPRISTONE; MITOTANE; OCTREOTIDE; PSYCHOTROPIC AGENT; RITANSERIN; SEROTONIN UPTAKE INHIBITOR; SOMATOSTATIN DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

ANXIETY NEUROSIS; BEHAVIOR THERAPY; CLINICAL FEATURE; COGNITIVE DEFECT; COGNITIVE THERAPY; CONVALESCENCE; CUSHING SYNDROME; DEPRESSION; DISEASE ASSOCIATION; HORMONE INHIBITION; HYPERCORTISOLISM; MANIA; MENTAL DISEASE; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PSYCHOBIOLOGY; QUALITY OF LIFE; REVIEW; STRESS;

EID: 0034998119     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200115050-00003     Document Type: Review

References (84)

1. 1. Sonino N, Fava GA. Psychological aspects of endocrine disease. Clin Endocrinol (Oxf) 1998; 49: 1-7
2. 2. Sonino N, Fava GA. Psychosomatic aspects of Cushing's disease. Psychother Psychosom 1998; 67: 140-6
3. 3. Boscaro M, Barzon L, Sonino N. The diagnosis of Cushing's syndrome: atypical presentations and laboratory pitfalls. Arch Intern Med 2000; 160: 3045-53
4. 4. Boscaro M, Barzon L, Fallo F, et al. Update on Cushing's syndrome. Lancet 2001; 357: 783-91
5. 5. Crosby SR, Steward MF, Ratcliffe JD, et al. Direct measurement of the precursors of adrenocorticotropin in human plasma by two-site immunoradiometric assay. J Clin Endocrinol Metab 1998; 67: 1272-7
6. 6. Lowry PJ, Linton EA, Hodgkinson SC. Analysis of peptide hormones of the hypothalamic pituitary adrenal axis using 'two-site' immunoradiometric assays. Horm Res 1989; 32: 25-9
7. 7. Samuels MH, Loriaux LD. Cushing's syndrome and the nodular adrenal gland. Endocrinol Metab Clin North Am 1994; 23: 555-69
8. 8. Lacroix A, Bolte E, Tremblay J, et al. Gastric inhibitory polypeptide-dependent Cortisol hypersecretion: a new cause of Cushing's syndrome. N Engl J Med 1992; 327: 974-80
9. 9. Reznik Y, Allali-Zerah V, Chayavialle JA, et al. Food dependent Cushing's syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide. N Engl J Med 1992; 327: 981-6
10. 10. Oldfield EH, Doppman JL, Nieman LK, et al. Petrosal sinus sampling with and without corticotrophin-releasing hormone for the differential diagnosis of Cushing's syndrome. N Engl J Med 1991; 325: 897-905
11. 11. White FE, White MC, Drury PL, et al. Value of computed tomography of the abdomen and chest in investigations of Cushing's syndrome. BMJ 1982; 284: 771-4
12. 12. Buchfelder M, Nistor R, Fahlbusch R, et al. The accuracy of CT and MR evaluation of the sella turcica for detection of adrenocorticotropin hormone-secreting adenomas in Cushing's disease. Am J Neuroradiol 1993; 4: 1183-90
13. 13. Colombo L, Loli P, Vignati F, et al. MR of corticotropin-secreting pituitary microadenomas. Am J Neuroradiol 1994; 15: 1591-5
14. 14. James RA. Octreotide and ectopic Cushing's syndrome: a commentary. Clin Endocrinol 1998; 49: 419-20
15. 15. de Herder WW, Lamberts SWJ. Tumor localization: the ectopic ACTH syndrome. J Clin Endocrinol Metab 1999; 84: 1184-5
16. 16. Urbanic RC, George JM. Cushing's disease: 18 years experience. Medicine 1981; 60: 14-24
17. 17. Ross EJ, Linch DC. Cushing's syndrome - killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet 1982; II: 646-9
18. 18. Sonino N, Boscaro M, Fallo F, et al. A clinical index for rating severity in Cushing's syndrome. Psychother Psychosom 2000; 69: 216-0
19. 19. Sonino N, Zielezny M, Fava GA, et al. Risk factors and long-term outcome in pituitary-dependent Cushing's disease. J Clin Endocrinol Metab 1996; 81: 2647-52
20. 20. Sonino N, Boscaro M. Medical therapy for Cushing's disease. Endocrinol Metab Clin North Am 1999; 28: 211-2
21. 21. Sonino N, Fava GA, Fallo F, et al. Effect of serotonin antagonists ritanserin and ketanserin in Cushing's disease. Pituitary 2000; 3: 55-60
22. 22. Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 1987; 317: 812-18
23. 23. Whitlock FA. Symptomatic affective disorders. Sydney: Academic Press, 1982
24. 24. Haskett RF. Diagnostic categorization of psychiatric disturbance in Cushing's syndrome. Am J Psychiatry 1985; 142: 911-16
25. 25. Hudson JI, Hudson MS, Griffing GT, et al. Phenomenology and family history of affective disorder in Cushing's disease. Am J Psychiatry 1987; 144: 951-3
26. 26. Loosen PT, Chambliss B, de Bold CR, et al. Psychiatric phenomenology in Cushing's disease. Pharmacopsychiatry 1992; 25: 192-8
27. 27. Sonino N, Fava GA, Belluardo P, et al. Course of depression in Cushing's syndrome: response to treatment and comparison with Graves' disease. Horm Res 1993; 39: 202-6
28. 28. Kelly WF. Psychiatric aspects of Cushing's syndrome. Q J Med 1996; 89: 543-1
29. 29. Sonino N, Fava GA, Raffi AR, et al. Clinical correlates of major depression in Cushing's disease. Psychopathology 1998; 31: 302-6
30. 30. Dorn LD, Burgess ES, Dubbert B, et al. Psychopathology in patients with endogenous Cushing's syndrome: atypical or melancholic features. Clin Endocrinol 1995; 43: 433-2
31. 31. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed, Washington, DC: American Psychiatric Association, 1994
32. 32. Fava G A. Affective disorders and endocrine disease. Psychosomatics 1994; 35: 341-53
33. 33. Fava GA, Sonino N. Depression associated with medical illness. CNS Drugs 1996; 5: 175-89
34. 34. Starkman MN, Schteingart DE, Schork MA. Depressed mood and other psychiatric manifestations of Cushing's syndrome. Psychosom Med 1981; 43: 3-18
35. 35. Lam RW, Stewart JN. The validity of atypical depression in DSM-IV. Compr Psychiatry 1996; 37: 375-83
36. 36. Fava GA. Subclinical symptoms in mood disorders. Psychol Med 1999; 29: 47-61
37. 37. Fava GA, Mangelli L. Subclinical symptoms of panic disorder. Psychother Psychosom 1999; 68: 281-9
38. 38. Schneider G, Kruse A, Nehen HG, et al. The prevalence and differential diagnosis of subclinical depressive syndromes in inpatients 60 years old and older. Psychother Psychosom 2000; 69: 251-60
39. 39. Fava GA, Sonino N. Psychosomatic medicine; emerging trends and perspectives. Psychother Psychosom 2000; 69: 184-97
40. 40. Meyer T, Klemme H, Herrmann C. Depression but not anxiety is a significant predictor of physicians' assessment of medical status in physically ill patients. Psychother Psychosom 2000; 69: 147-54
41. 41. Fava M, Rankin MA. Wright JE, et al. Anxiety disorders in major depression. Comp Psychiatry 2000; 41: 97-102
42. 42. Starkman MN, Schteingart DE, Schork MA. Correlation of bedside cognitive and neuropsychological tests in patients with Cushing's syndrome. Psychosomatics 1986; 27: 508-11
43. 43. Mauri M, Sinforiani E, Bono G, et al. Memory impairment in Cushing's disease. Acta Neurol Scand 1993; 87: 52-5
44. 44. Forget H, Lacroix A, Somma M. et al. Cognitive decline in patients with Cushing's syndrome. J Internat Neuropsychol Soc 2000; 6: 20-9
45. 45. Simmons NE, Do HM, Lipper MH, et al. Cerebral atrophy in Cushing's disease. Surg Neurol 2000; 53: 72-6
46. 46. Sonino N. From the lesson of Harvey Cushing to current knowledge: psychosocial aspects of endocrine disease. Psychother Psychosom 1997; 66: 113-6
47. 47. Cushing H. Psychic disturbances associated with disorders of the ductless glands. Am J Insanity 1913; 69: 965-0
48. 48. Trethowan WH, Cobb S. Neuropsychiatric aspects of Cushing's syndrome. AMA Arch Neurol Psychiat 1952; 67: 283-309
49. 49. Gifford S. Gunderson JG. Cushing's disease as a psychosomatic disorder. Medicine 1970; 49: 397-409
50. 50. Cohen SI. Cushing's syndrome. A psychiatric study of 29 patients. Br J Psychiatry 1988; 120-4
51. 51. Sonino N, Fava GA, Grandi S, et al. Stressful life events in the pathogenesis of Cushing's syndrome. Clin Endocrinol 1988; 29: 617-23
52. 52. Sonino N, Fava GA, Boscaro M. A role for life events in the pathogenesis of Cushing's disease. Clin Endocrinol 1993; 38: 261-4
53. 53. Paykel ES. The interview for recent life events. Psychol Med 1997; 27: 301-10
54. 54. Mazet Ph, Simon D, Luton JP, et al. Syndrome de Cushing: symptomatologie psychique et personalité de 50 malades. Nouv Press Med 1988; 10: 2565-70
55. 55. Fava GA, Munari F, Pavan L, et al. Life events and depression. J Affect Disord 1981; 3: 159-65
56. 56. Sonino N, Girelli ME, Boscaro M, et al. Life events in the pathogenesis of Graves disease. Acta Endocrinol 1993; 128: 293-6
57. 57. Radosavljevic VR, Jankovic SN, Marinkovic JM. Stressful life events in the pathogenesis of Graves' disease. Eur J Endocrinol 1996; 134: 699-701
58. 58. Kung AWC. Life events, daily stresses and coping in patients with Graves' disease. Clin Endocrinol 1995; 42: 303-8
59. 59. Krieger DT. Physiopathology of Cushing's disease. Endocr Rev 1983; 4: 22-43
60. 60. Biondi M, Picardi A. Psychological stress and neuroendocrine function in humans. Psychother Psychosom 1999; 68: 114-50
61. 61. Sonino N, Fava GA. Serotonin, Cushing's disease and depression. Psychother Psychosom 1996; 65: 63-5
62. 62. de Kloet ER, Rots NY, Cools AR. Brain-corticosteroid hormone dialogue: slow and persistent. Cell Mol Neurobiol 1996; 16: 345-56
63. 63. Seeman T, McEwen BS. Impact of social environment characteristics on neuroendocrine regulation. Psychosom Med 1996; 58: 459-71
64. 64. Heim C, Owens MJ, Plotsky PM, et al. Persistent changes in corticotrophin-releasing factor systems due to early life stress. Psychopharmacol Bull 1997; 33: 185-92
65. 65. Burgess E, Dom LD, Haaga DAF, et al. Sociotropy, autonomy, stress, and depression in Cushing syndrome. J Nerv Ment Dis 1996; 184: 362-7
66. 66. Patten SB, Love EJ. Drug-induced depression. Psychother Psychosom 1997; 66: 63-73
67. 67. Kelly WF, Kelly MJ, Faragher B. A prospective study of psychiatric and psychological aspects of Cushing's syndrome. Clin Endocrinol 1996; 45: 715-20
68. 68. Dorn LD, Burgess ES, Friedman TC, et al. The longitudinal course of psychopathology in Cushing's syndrome after correction of hypercortisolism. J Clin Endocrinol Metab 1997; 82: 912-9
69. 69. Voigt KH, Bossert S, Bretschneider S, et al. Disturbed cortisol secretion in man. Psychiatry Res 1985; 15: 341-50
70. 70. Taft P, Martin FIR, Melick R. Cushing's syndrome. A review of the response to treatment in 42 patients. Australas Ann Med 1970; 4: 295-303
71. 71. Sonino N. Fallo F, Opocher G, et al. Hypertension in Cushing's syndrome. Med Sci Res 1992; 20: 431-4
72. 72. Fallo F, Sonino N, Barzon L, et al. Effects of surgical treatment on hypertension in Cushing's syndrome. Am J Hypertens 1996; 9: 77-80
73. 73. Regenstein QR, Rose LI, Williams GH. Psychopathology in Cushing's syndrome. Arch Intern Med 1972; 130: 114-7
74. 74. Jacobs BL, van Praag H, Gage FH. Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol Psychiatry 2000; 5: 262-9
75. 75. Starkman MN, Giordani B. Gerbaski SS, et al. Decrease in cortical reverses human hippocampal atrophy following treatment of Cushing's disease. Biol Psychiatry 1999; 46: 1595-602
76. 76. Jeffcoate WJ, Silverstone JT, Edwards CRW, et al. Psychiatric manifestations of Cushing's syndrome: response to lowering of plasma cortisol. Q J Med 1979, 48: 465-72
77. 77. Kramlinger KG, Peterson GC, Watson PK,et al. Metyrapone for depression and delirium secondary to Cushing's syndrome. Psychosomatics 1985; 26: 67-71
78. 78. van der Lely AJ, Foeken K, van der Mast RC, et al. Rapid reversal of acute psychosis in the Cushing's syndrome with the cortisol-receptor antagonist mifepristone (RU 486). Ann Intern Med 1991; 114: 143-4
79. 79. Sonino N, Boscaro M, Ambroso G, et al. Prolonged treatment of Cushing's disease with metyrapone and aminoglutethimide. IRCS Med Sci 1986; 14: 485-6
80. 80. Pelton GH. Antiglucocorticoidid medication for the treatment of depression. Psychiat Ann 2000; 30: 139-46
81. 81. Starkman MN, Schteingart DE, Schork MA. Cushing's syndrome after treatment. Psychiatry Res 1986; 17: 177-8
82. 82. Starkman MN, Gebarski SS, Berent S, et al. Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing's syndrome. Biol Psychiatry 1992; 32: 756-65
83. 83. Momose KJ, Kjellberg RN, Kliman B. High incidence of cortical atrophy of the cerebral and cerebellar hemispheres in Cushing's disease. Radiology 1971; 99: 341-8
84. 84. Dubrovsky B. Effects of adrenal cortex hormones on limbic structures. J Psychiat Neurosci 1993; 18: 4-16